Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

fingolimod hydrochloride

Known as: 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride, Hydrochloride, Fingolimod, 2-Amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol Hydrochloride 
A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND Disease-modifying therapies (DMTs) are indicated to reduce relapse rates and slow disease progression for relapsing… Expand
Is this relevant?
2017
2017
Abstract This study was focused on the fabrication, statistical optimization and in vitro characterization of poly… Expand
Is this relevant?
2015
2015
This randomized, double-blind, placebo-controlled, 6-arm, parallel-design study investigated cardiac and hematological… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Objective: To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
BackgroundA 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with relapsing-remitting… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Fingolimod 0·5 mg once daily is approved for treatment of relapsing multiple sclerosis (MS). In the phase 3, 2-year… Expand
Is this relevant?
Review
2011
Review
2011
Until recently, all approved multiple sclerosis (MS) disease treatments were administered parenterally. Oral fingolimod was… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Background: The oral immunomodulator fingolimod (FTY720) has recently been shown to be highly effective in relapsing-remitting… Expand
  • figure 1
  • figure 2
Is this relevant?
2011
2011
Background: There has been poor translation for the use of immunosuppressive agents from experimental autoimmune… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2009
2009
The immunomodulator fingolimod (FTY720) induces lymphopenia by inhibiting lymphocyte egress from thymus and secondary lymphoid… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?